Compare PRM & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRM | STVN |
|---|---|---|
| Founded | 2018 | 1949 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Containers/Packaging |
| Sector | Consumer Discretionary | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.2B |
| IPO Year | N/A | 2021 |
| Metric | PRM | STVN |
|---|---|---|
| Price | $23.02 | $14.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $25.50 | $25.13 |
| AVG Volume (30 Days) | ★ 998.7K | 594.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 0.42% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.52 | $10.26 |
| Revenue Next Year | $11.03 | $10.02 |
| P/E Ratio | $51.56 | ★ $27.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.76 | $13.91 |
| 52 Week High | $29.88 | $28.00 |
| Indicator | PRM | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 33.33 | 41.94 |
| Support Level | $22.58 | $14.03 |
| Resistance Level | $23.46 | $17.14 |
| Average True Range (ATR) | 0.92 | 0.87 |
| MACD | -0.14 | 0.08 |
| Stochastic Oscillator | 11.30 | 22.21 |
Perimeter Solutions Inc is a solutions provider for the Fire Safety and Specialty Products industries. The Company's products and operations are managed and reported in two operating segments. Its Fire Safety segment provides fire retardants and firefighting foams, as well as specialized equipment and services typically offered in conjunction with the Company's retardant and foam products. The Specialty Products segment includes operations that develop, produce and market products for non-fire safety markets. Specialty Products segment is Phosphorus Pentasulfide (P2S5) based lubricant additives. P2S5 is also used in pesticide and mining chemicals applications, and emerging electric battery technologies.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.